After the slimming effect of Ozempic and Zepbound earned billions for Novo Nordisk and Eli Lilly, another class of ...

The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple ...

Trans-Tasman drug developer Aft Pharmaceuticals is targeting lucrative niche diseases its Big Pharma rivals have ignored ...

European shares European shares were higher on Monday as investors reacted to U.S. President Donald Trump delaying the roll ...

Zealand Pharma A/S + Watchlist ZEAL DK Closed Last Updated: May 23, 2025 5:20 p.m. CEDT Delayed quote kr. 408.90 4.40 1.09% Previous Close kr.404.50 Toggle Chart Options Advanced Charting Range ...

Zealand Pharma named Steven Johnson as chief development officer. Mirum Pharmaceuticals appointed Doug Sheehy as chief legal officer. Arbor Bio appointed Don Haut, Ph.D., as chief business officer.

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of ...

Compare to Benchmark: DJIA S&P 500 GLOBAL DOW NASDAQ Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and ...

Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer Steven will lead the ...

Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer Steven will lead the ...

Zealand Pharma A/S, a biotechnology company, has appointed Steven Johnson as Chief Development Officer. Johnson will join the executive team to lead regulatory and development strategies. His ...